Filing Flows › Veracyte (VCYT) › R&D spending
Veracyte (VCYT) R&D spending by quarter
Veracyte's R&D spending was $32.2M in Q3 2026 (third quarter 2026), +9% from Q2 2026. Over the last 7 quarters it ranged from $16.0M (Q3 2025) to $32.2M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $32.2M | +9% | +101% |
| Q2 2026 | $29.4M | +9% | +81% |
| Q1 2026 | $27.1M | +30% | +53% |
| Q4 2025 | $20.8M | +30% | — |
| Q3 2025 | $16.0M | -2% | — |
| Q2 2025 | $16.3M | -8% | — |
| Q1 2025 | $17.7M | — | — |
Q3 2026 at a glance
Veracyte, Q3 2026: revenue $152M (+15% year over year), operating margin 10.9%, net earnings $31.5M, operating cash flow $40.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Veracyte's R&D spending?
Veracyte's R&D spending was $32.2M in Q3 2026 (third quarter 2026), +9% from Q2 2026.
How has Veracyte's R&D spending changed?
Over the last 7 quarters it ranged from $16.0M (Q3 2025) to $32.2M (Q3 2026).